MTOR and neoplasm: Landa et al. [28] also performed next-generation sequencing (NGS) of 341 cancer genes from 117 patient-derived PDTC and ATC and analysed the transcriptome of a representative subset of 37 tumours and found a high prevalence of TP53, TERT promoter, PI3K/AKT/mTOR pathway effectors, SWI/SNF subunits, and histone methyltransferases, beyond the BRAF and RAS mutations, which were the predominant drivers.